Symbicort provides the inhaled corticosteroid budesonide (Pulmicort) and the rapid and long-acting bronchodilator formoterol (Oxis) in a single inhaler (Turbuhaler).
Symbicort is indicated for the maintenance treatment of asthma in adults and children aged 6 years and above, where the combination of an inhaled corticosteroid and a long-acting beta 2- agonist is appropriate.
Did you know?
AstraZeneca has a range of product specific and disease area websites for international healthcare professionals and patients. Links to this information can be found below.
Links to country-specific websites can be found using the AstraZeneca websites list.
If you still have a question regarding our drug portfolio you can Contact us.
Not signed in
Page tools
Share price
- London
-
26.95 GBP - New York
-
44.82 USD - Stockholm
-
310.10 SEK
At 21-Nov-2009 03:08 GMT
Detailed share priceIntroduction to AstraZeneca
Our responsibility
We continue to communicate openly on a range of issues, including:
